Physician profile
War War Ko
NPI 1386207421
$2,082.63
in general payments reported to CMS, 2019-2025
17 companies · $2,015 in 2025
The $2,015 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.25 · 2024: $47.52 · 2025: $2,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $319.13 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $300.63 | 2025 | Evenity, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $273.49 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $242.70 | 2025 | Voquezna |
| Ardelyx, INC. | $163.50 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $122.17 | 2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $90.60 | 2025 | Breztri |
| Agios Pharmaceuticals, INC. | $86.57 | 2025 | Pyrukynd |
| Ibsa Pharma INC. | $84.38 | 2025 | Tirosint, Flector, Licart |
| Kowa Pharmaceuticals America, INC. | $83.93 | 2025 | Zoryve |
| Abbvie INC. | $61.50 | 2022-2025 | |
| Gilead Sciences, INC. | $49.51 | 2025 | |
| Merck Sharp & Dohme LLC | $47.48 | 2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Lilly USA, LLC | $45.78 | 2025 | Jardiance, Mounjaro, Zepbound |
| Redhill Biopharma INC. | $38.23 | 2025 | Talicia |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $36.54 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.49 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw War War Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.